[HTML][HTML] Glycolipid antigen induces long-term natural killer T cell anergy in mice

VV Parekh, MT Wilson… - The Journal of …, 2005 - Am Soc Clin Investig
VV Parekh, MT Wilson, D Olivares-Villagómez, AK Singh, L Wu, CR Wang, S Joyce
The Journal of clinical investigation, 2005Am Soc Clin Investig
Natural killer T (NKT) cells recognize glycolipid antigens presented by the MHC class I–
related glycoprotein CD1d. The in vivo dynamics of the NKT cell population in response to
glycolipid activation remain poorly understood. Here, we show that a single administration of
the synthetic glycolipid α-galactosylceramide (α-GalCer) induces long-term NKT cell
unresponsiveness in mice. NKT cells failed to proliferate and produce IFN-γ upon α-GalCer
restimulation but retained the capacity to produce IL-4. Consequently, we found that …
Natural killer T (NKT) cells recognize glycolipid antigens presented by the MHC class I–related glycoprotein CD1d. The in vivo dynamics of the NKT cell population in response to glycolipid activation remain poorly understood. Here, we show that a single administration of the synthetic glycolipid α-galactosylceramide (α-GalCer) induces long-term NKT cell unresponsiveness in mice. NKT cells failed to proliferate and produce IFN-γ upon α-GalCer restimulation but retained the capacity to produce IL-4. Consequently, we found that activation of anergic NKT cells with α-GalCer exacerbated, rather than prevented, B16 metastasis formation, but that these cells retained their capacity to protect mice against experimental autoimmune encephalomyelitis. NKT cell anergy was induced in a thymus-independent manner and maintained in an NKT cell–autonomous manner. The anergic state could be broken by IL-2 and by stimuli that bypass proximal TCR signaling events. Collectively, the kinetics of initial NKT cell activation, expansion, and induction of anergy in response to α-GalCer administration resemble the responses of conventional T cells to strong stimuli such as superantigens. Our findings have important implications for the development of NKT cell–based vaccines and immunotherapies.
The Journal of Clinical Investigation